News Cutia Therapeutics

Stocks

2487

KYG2606C1006

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:08 2026-10-30 EDT			5-day change	1st Jan Change
0.6900 ^HKD	-4.17%		-1.43%	-84.80%

10-21	Cutia, Rejuven Amend Agreement to Boost CU-20401's Coverage; Shares Fall 5%	MT
10-19	Fangzhou Inc. and Cutia Therapeutics Partners to Advance Ai-Powered Dermatology and Chronic Health Management	CI

All News

Mentions Relevance

10-21	Cutia, Rejuven Amend Agreement to Boost CU-20401's Coverage; Shares Fall 5%	MT
10-05	Cutia Therapeutics commences an Equity Buyback Plan for 36,336,827 shares, representing 10% of its issued share capital, under the authorization approved on June 26, 2026.	CI
09-30	Cutia Therapeutics to Launch Up to 30 Million Yuan Share Buyback	MT
09-30	Cutia Therapeutics Announces Resignation of Huang Yuqing as Chief Financial Officer, Effective September 30, 2026	CI
09-30	Cutia Therapeutics Announces Board Changes, Effective September 30, 2026	CI
09-21	Cutia Therapeutics Announces Cu-40102 Topical Finasteride Spray Obtains Marketing Approval by Macao Pharmaceutical Administration Bureau	CI
09-21	Cutia Therapeutics Gets Macao Approval for Topical Finasteride Spray	MT
09-03	Cutia Therapeutics' Marketing Application for Botox Product Accepted in China	MT
09-02	Cutia Therapeutics Announces Biologics License Application for Cu-20101 Accepted by Nmpa	CI
08-31	Cutia Therapeutics Reports Earnings Results for the Half Year Ended June 30, 2026	CI
05-07	Cutia Therapeutics Announces Drug Marketing Authorization for CU-30101 Localized Topical Lidocaine and Tetracaine Cream	CI
05-06	Cutia Therapeutics' Topical Anesthetic CU-30101 Approved in China	MT
05-06	Cutia Therapeutics says CU-30101 obtains drug marketing authorization by NMPA China	RE
04-12	Cutia Therapeutics Completes Phase 3 Trial for Botulinum Toxin Product	MT
04-12	Cutia Therapeutics says completion of phase III clinical trial of CU-20101	RE
04-12	Cutia Therapeutics Announces Completion of Phase III Clinical Trial of CU-20101 Botulinum Toxin Type A for Injection for Improving Moderate to Severe Glabellar Lines in China	CI
03-24	Cutia Therapeutics Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-24	Cutia Therapeutics' Loss Narrows in 2025 as Revenue Rises	MT
03-15	Cutia Therapeutics says CU-40104 obtains clinical trial approval from NMPA, China	RE
03-15	Cutia Therapeutics Receives Chinese Regulatory Approval to Begin Trials of Hair Loss Drug	MT
03-15	Cutia Therapeutics Announces Clinical Trial Approval For Cu-40104 (Topical Dutasteride Agent) By the NMPA	CI
01-19	Cutia Therapeutics Announces Cu-20101 for Improving Moderate to Severe Glabellar Lines Achieved Positive Topline Results from Phase III Clinical Trial in China	CI
01-18	Cutia Therapeutics Says Phase 3 Trial of CU-20101 Meets Key Endpoints in China	MT
12-30	Cutia Therapeutics Announces Board Changes, Effective December 30, 2025	CI
11-18	China Accepts Cutia Therapeutics' ANDA Filing for New Topical Finasteride Spray	MT